13 results
Objective: The principal objective is To evaluate the long-term safety and maintenance of efficacy of BOTOX® (200 U) injected into the detrusor for the treatment of urinary incontinence caused by neurogenic detrusor overactivity in patients who have…
To evaluate the efficacy and safety of BOTOX® 100 U compared with placebo in patientswith idiopathic OAB with urinary incontinence whose symptoms have not been adequatelymanaged with anticholinergic therapy.
To evaluate the responsiveness of the extensor digitorum brevis (EDB) muscle to BoNT/A in extremities affected and unaffected by CRPS.
To determine the effect on lower urinary tract symptoms and to determine urodynamic and histologic changes after intraprostatic botulinum toxin type A injection.
Objective: The principal objective is to evaluate the safety and efficacy of two doses of BOTOX (200 Units or 300 Units) compared with placebo injected into the bladder wall in patients who have urinary incontinence due to neurogenic detrusor…
- To assess the effect of food (high-fat) on the bioavailability and pharmacokinetic (PK)- profile of a solid dosage formulation of JNJ-67953964.- To assess the effects of repeated QD administration of 200 mg of itraconazole (steady state) on the…
The objective of this study is to investigate whether BTA injection in the pelvic floor muscle is an effective treatment for patients with chronic pelvic pain and pelvic floor hypertonicity.
- Can early Botox-injections in the bladder of patients with meningomyelocèle (MMC) prevent deterioration of the bladder and renal function?- Can early Botox-injections in the bladder of patients with meningomyelocèle (MMC) decrease the need for an…
1. We want to study the success rate of OAHM withdrawal in patients with chronic migraine related to support by a headache nurse, and onabotulinum toxin A injections during the withdrawal period, and the influence of comorbid depression.2. We want…
To determine the proportion of successful alignment after treatment of infantile esotropia with Botox.
Primary To confirm superiority on body weight reduction of CagriSema 2.4 mg/2.4 mg versus placebo as adjuncts to reduced-calorie diet andincreased physical activity in participants with overweight or obesity. Secondary To confirm superiority of…
Primary: to confirm non-inferiority of CagriSema 2.4 mg/2.4 mg versus placebo with respect to time to first major adverse cardiovascular event (MACE). Secondary: to confirm superiority of CagriSema 2.4 mg/2.4 mg versus placebo with respect to time…
The main objective of this trial is to investigate glucagon receptor occupancy of BI 456906 in the liver with PET imaging using the radiolabeled tracer [68Ga]Ga-DO3A-VS-Cys40-Tuna-2.The secondary objectives is to investigate the GLP-1 receptor…